SI2790705T1 - Use of activity inhibitors or PI3K function - Google Patents
Use of activity inhibitors or PI3K function Download PDFInfo
- Publication number
- SI2790705T1 SI2790705T1 SI201231220T SI201231220T SI2790705T1 SI 2790705 T1 SI2790705 T1 SI 2790705T1 SI 201231220 T SI201231220 T SI 201231220T SI 201231220 T SI201231220 T SI 201231220T SI 2790705 T1 SI2790705 T1 SI 2790705T1
- Authority
- SI
- Slovenia
- Prior art keywords
- pyrimidin
- methoxy
- yloxy
- pyrrolidin
- pyridin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161576194P | 2011-12-15 | 2011-12-15 | |
| PCT/IB2012/057332 WO2013088404A1 (en) | 2011-12-15 | 2012-12-14 | Use of inhibitors of the activity or function of PI3K |
| EP12818825.7A EP2790705B1 (en) | 2011-12-15 | 2012-12-14 | Use of inhibitors of the activity or function of pi3k |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2790705T1 true SI2790705T1 (en) | 2018-03-30 |
Family
ID=47603895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201231220T SI2790705T1 (en) | 2011-12-15 | 2012-12-14 | Use of activity inhibitors or PI3K function |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US9949979B2 (enExample) |
| EP (1) | EP2790705B1 (enExample) |
| JP (1) | JP6117235B2 (enExample) |
| KR (1) | KR102038462B1 (enExample) |
| CN (1) | CN103998042B (enExample) |
| AP (1) | AP3849A (enExample) |
| AU (1) | AU2012354094C1 (enExample) |
| BR (1) | BR112014014327A2 (enExample) |
| CA (1) | CA2857302C (enExample) |
| DK (1) | DK2790705T3 (enExample) |
| EA (1) | EA029473B1 (enExample) |
| ES (1) | ES2661510T3 (enExample) |
| GT (1) | GT201400114A (enExample) |
| HU (1) | HUE036052T2 (enExample) |
| MA (1) | MA35857B1 (enExample) |
| MX (1) | MX351530B (enExample) |
| NI (1) | NI201400056A (enExample) |
| NO (1) | NO2896266T3 (enExample) |
| PH (1) | PH12014501348A1 (enExample) |
| PL (1) | PL2790705T3 (enExample) |
| PT (1) | PT2790705T (enExample) |
| SI (1) | SI2790705T1 (enExample) |
| TN (1) | TN2014000230A1 (enExample) |
| WO (1) | WO2013088404A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
| JP6117235B2 (ja) | 2011-12-15 | 2017-04-19 | ノバルティス アーゲー | Ｐｉ３ｋの活性または機能の阻害剤の使用 |
| IN2015DN03235A (enExample) | 2012-11-07 | 2015-10-02 | Karus Therapeutics Ltd | |
| ES2688815T3 (es) | 2013-05-10 | 2018-11-07 | Karus Therapeutics Limited | Inhibidores de histona desacetilasa novedosos |
| US20150105383A1 (en) * | 2013-10-10 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | HDAC Inhibitors, Alone Or In Combination With PI3K Inhibitors, For Treating Non-Hodgkin's Lymphoma |
| JP6878004B2 (ja) | 2013-12-13 | 2021-05-26 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | リンパ形質細胞性リンパ腫を処置する方法 |
| JP6879740B2 (ja) | 2013-12-13 | 2021-06-02 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | リンパ形質細胞性リンパ腫を処置する方法 |
| WO2015162584A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Crystalline forms of the sulfate salt of n-[5-(3-imidazol-1-yl-4-methanesulfonyl-phenyl)-4-methyl-thiazol-2-yl]-acetamide |
| US10112957B2 (en) | 2014-10-22 | 2018-10-30 | Dana-Farber Cancer Institute, Inc. | Thiazolyl-containing compounds for treating proliferative diseases |
| GB201419228D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
| GB201419264D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
| MD3762368T2 (ro) | 2018-03-08 | 2022-07-31 | Incyte Corp | Compuși diol aminopirazină ca inhibitori ai PI3K-Y |
| WO2019244049A1 (en) * | 2018-06-19 | 2019-12-26 | Novartis Ag | Cyanotriazole compounds and uses thereof |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| CA3106470A1 (en) | 2018-07-17 | 2020-01-23 | Nippon Chemiphar Co., Ltd. | T-type calcium channel blocker |
| EP3950059A4 (en) | 2019-03-29 | 2023-01-11 | Nippon Chemiphar Co., Ltd. | USE OF A T-TYPE CALCIUM CHANNEL BLOCKER TO TREAT PRURITUS |
| WO2023170680A1 (en) | 2022-03-08 | 2023-09-14 | Equashield Medical Ltd | Fluid transfer station in a robotic pharmaceutical preparation system |
| CN114957676B (zh) * | 2022-06-22 | 2023-05-16 | 安徽工程大学 | 一种利用反溶剂沉积快速调控水分活度制备美拉德反应产物的方法 |
| CN117534672A (zh) * | 2023-11-10 | 2024-02-09 | 北京康立生医药技术开发有限公司 | 一种apds治疗药物新的制备方法 |
Family Cites Families (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5300645A (en) | 1993-04-14 | 1994-04-05 | Eli Lilly And Company | Tetrahydro-pyrido-indole |
| US5858753A (en) | 1996-11-25 | 1999-01-12 | Icos Corporation | Lipid kinase |
| US5939421A (en) | 1997-07-01 | 1999-08-17 | Signal Pharmaceuticals, Inc. | Quinazoline analogs and related compounds and methods for treating inflammatory conditions |
| US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
| WO2001085986A2 (en) | 2000-05-10 | 2001-11-15 | Icos Corporation | Phosphatidyl inositol 3-kinase delta binding partner |
| DE10043667A1 (de) | 2000-09-05 | 2002-03-14 | Merck Patent Gmbh | 2-Guanidino-4-aryl-chinazoline |
| SG159378A1 (en) | 2000-11-07 | 2010-03-30 | Novartis Ag | Indolylmaleimide derivatives as protein kinase c inhibitors |
| US7071189B2 (en) | 2001-04-27 | 2006-07-04 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent containing the same as active ingredient |
| PE20040079A1 (es) | 2002-04-03 | 2004-04-19 | Novartis Ag | Derivados de indolilmaleimida |
| WO2004052359A1 (en) | 2002-12-09 | 2004-06-24 | The Board Of Regents Of The University Of Texas System | Methods for selectively inhibiting janus tyrosine kinase 3 (jak3) |
| BR0317749A (pt) | 2002-12-27 | 2005-11-22 | Angeletti P Ist Richerche Bio | Composto, composição farmacêutica, e, uso de um composto |
| US20050043239A1 (en) | 2003-08-14 | 2005-02-24 | Jason Douangpanya | Methods of inhibiting immune responses stimulated by an endogenous factor |
| US20050054614A1 (en) | 2003-08-14 | 2005-03-10 | Diacovo Thomas G. | Methods of inhibiting leukocyte accumulation |
| US20080207613A1 (en) | 2004-01-12 | 2008-08-28 | Cytopia Research Pty Ltd | Selective Kinase Inhibitors |
| JP2007524673A (ja) | 2004-01-23 | 2007-08-30 | アムジエン・インコーポレーテツド | バニロイド受容体リガンドと治療におけるその使用 |
| US8048454B2 (en) | 2004-03-09 | 2011-11-01 | Michael Martin | Methods and compositions related to regulation of cytokine production by glycogen synthase kinase 3 (GSK-3) |
| EP1761540B1 (en) | 2004-05-13 | 2016-09-28 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
| WO2005112935A1 (en) | 2004-05-13 | 2005-12-01 | Vanderbilt University | Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis |
| PT2298768E (pt) | 2004-06-11 | 2012-12-05 | Japan Tobacco Inc | Derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetra-hidro-2hpirido[ 2,3-d]pirimidina e compostos relacionados para o tratamento do cancro |
| GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| US20060128710A1 (en) | 2004-12-09 | 2006-06-15 | Chih-Hung Lee | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof |
| KR20060079121A (ko) | 2004-12-31 | 2006-07-05 | 에스케이케미칼주식회사 | 당뇨 및 비만 치료예방에 유효한 퀴나졸린 유도체 |
| WO2006119504A2 (en) | 2005-05-04 | 2006-11-09 | Renovis, Inc. | Fused heterocyclic compounds, and compositions and uses thereof |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| NZ565749A (en) | 2005-08-26 | 2010-12-24 | Serono Lab | Pyrazine derivatives and use as PI3K inhibitors |
| GB0520657D0 (en) | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
| AU2006329202A1 (en) | 2005-12-21 | 2007-06-28 | Painceptor Pharma Corporation | Compositions and methods for modulating gated ion channels |
| GB0612630D0 (en) | 2006-06-26 | 2006-08-02 | Novartis Ag | Organic compounds |
| US8673929B2 (en) | 2006-07-20 | 2014-03-18 | Gilead Sciences, Inc. | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections |
| RU2009106722A (ru) * | 2006-07-28 | 2010-09-10 | Новартис АГ (CH) | 2,4-замещенные хиназолины в качестве ингибиторов липидной киназы |
| EP1891958A1 (en) * | 2006-08-03 | 2008-02-27 | Universite Pierre Et Marie Curie (Paris Vi) | Rho/Rock/PI3/Akt kinase inhibitors for the treatment of diseases associated with protozoan parasites. |
| JP5313909B2 (ja) | 2006-11-13 | 2013-10-09 | アイコス コーポレイション | 炎症性疾患および癌の処置のためのチエノピリミジノン |
| RS54706B1 (sr) | 2007-03-23 | 2016-08-31 | Amgen Inc. | Heterociklična jedinjenja i njihove upotrebe |
| AU2008231384B2 (en) | 2007-03-23 | 2011-09-15 | Amgen Inc. | Heterocyclic compounds and their use |
| MX2009010050A (es) | 2007-03-23 | 2009-10-12 | Amgen Inc | Derivados de quinolina o quinoxalina 3-sustituidos y su uso como inhibidores de fosfotidilinositol 3-cinasa (p13k). |
| JP5396379B2 (ja) | 2007-04-02 | 2014-01-22 | エボテック・アーゲー | ピリド−２−イル縮合複素環式化合物ならびにその組成物および使用 |
| MX2009010886A (es) | 2007-04-12 | 2009-12-14 | Hoffmann La Roche | Derivados de pirimidina como inhibidores de fosfatidilinositol-3-c inasa. |
| BRPI0810646A2 (pt) | 2007-04-12 | 2014-11-04 | Hoffmann La Roche | " compostos farmacêuticos ". |
| GB0707087D0 (en) | 2007-04-12 | 2007-05-23 | Piramed Ltd | Pharmaceutical compounds |
| WO2008130481A1 (en) | 2007-04-17 | 2008-10-30 | Renovis, Inc. | 2-cyanophenyl fused heterocyclic compounds, and compositions and uses thereof |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| EP2154965A4 (en) | 2007-05-29 | 2011-08-17 | Glaxosmithkline Llc | NAPHTHYRIDINE DERIVATIVES AS P13 KINASE INHIBITORS |
| CN101679456B (zh) | 2007-06-12 | 2012-09-05 | 霍夫曼-拉罗奇有限公司 | 噻唑并嘧啶类和它们作为磷脂酰肌醇3-激酶的抑制剂的应用 |
| WO2008152394A1 (en) | 2007-06-12 | 2008-12-18 | F.Hoffmann-La Roche Ag | Pharmaceutical compounds |
| WO2008152387A1 (en) | 2007-06-12 | 2008-12-18 | F.Hoffmann-La Roche Ag | Quinazoline derivatives as pi3 kinase inhibitors |
| UY31137A1 (es) * | 2007-06-14 | 2009-01-05 | Smithkline Beecham Corp | Derivados de quinazolina como inhibidores de la pi3 quinasa |
| RU2341527C1 (ru) | 2007-07-17 | 2008-12-20 | Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" | Аннелированные азагетероциклы, включающие пиримидиновый фрагмент, способ их получения и ингибиторы pi3k киназ |
| TW200908984A (en) | 2007-08-07 | 2009-03-01 | Piramal Life Sciences Ltd | Pyridyl derivatives, their preparation and use |
| WO2009036768A2 (en) | 2007-09-19 | 2009-03-26 | H. Lundbeck A/S | Diagnosing potential weight gain in a subject |
| GB2467670B (en) | 2007-10-04 | 2012-08-01 | Intellikine Inc | Chemical entities and therapeutic uses thereof |
| US20100298289A1 (en) | 2007-10-09 | 2010-11-25 | Ucb Pharma, S.A. | Heterobicyclic compounds as histamine h4-receptor antagonists |
| WO2009058361A1 (en) * | 2007-10-31 | 2009-05-07 | Dynavax Technologies Corp. | Inhibition of type i ifn production |
| GEP20125635B (en) | 2007-11-13 | 2012-09-10 | Icos Corp | Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| CA2711558C (en) | 2008-01-04 | 2016-12-13 | Intellikine, Inc. | Phosphatidyl inositol-3 kinase inhibiting compounds |
| JP2011515462A (ja) | 2008-03-27 | 2011-05-19 | アウククランド ウニセルビセス リミテッド | 置換されたピリミジン、及びトリアジン、並びに癌療法におけるこれらの使用 |
| US8436005B2 (en) | 2008-04-03 | 2013-05-07 | Abbott Laboratories | Macrocyclic pyrimidine derivatives |
| EP2280705B1 (en) | 2008-06-05 | 2014-10-08 | Glaxo Group Limited | Novel compounds |
| JP5502077B2 (ja) | 2008-06-05 | 2014-05-28 | グラクソ グループ リミテッド | 新規な化合物 |
| EP2300437B1 (en) | 2008-06-05 | 2013-11-20 | Glaxo Group Limited | Benzpyrazol derivatives as inhibitors of pi3 kinases |
| BRPI0914223A2 (pt) | 2008-06-19 | 2019-09-24 | Millennium Pharm Inc | derivados de tiofeno ou tiazol e seus usos como inibidores de p13k |
| JP2011527342A (ja) | 2008-07-07 | 2011-10-27 | エックスカバリー ホールディング カンパニー エルエルシー | Ｐｉ３ｋアイソフォーム選択的阻害剤 |
| AU2009268611B2 (en) | 2008-07-08 | 2015-04-09 | Intellikine, Llc | Kinase inhibitors and methods of use |
| JP5731978B2 (ja) | 2008-09-26 | 2015-06-10 | インテリカイン， エルエルシー | 複素環キナーゼ阻害剤 |
| BRPI0919816A2 (pt) * | 2008-09-26 | 2019-09-24 | Eisai R&D Man Co Ltd | uso compostos benzoxazólicos no tratamento de malária |
| KR20160091440A (ko) | 2008-11-13 | 2016-08-02 | 길리아드 칼리스토가 엘엘씨 | 혈액 종양에 대한 요법 |
| US20110269779A1 (en) | 2008-11-18 | 2011-11-03 | Intellikine, Inc. | Methods and compositions for treatment of ophthalmic conditions |
| EP2365810A2 (en) | 2008-12-04 | 2011-09-21 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders |
| EP2406255B1 (en) | 2009-03-09 | 2015-04-29 | Glaxo Group Limited | 4-oxadiazol-2-yl-indazoles as inhibitors of pi3 kinases |
| CN102481282A (zh) | 2009-03-24 | 2012-05-30 | 新加坡国立大学 | 青蒿素衍生物用于治疗哮喘和慢性阻塞性肺病(copd)的用途 |
| CA2756347A1 (en) | 2009-03-24 | 2010-09-30 | Gilead Calistoga Llc | Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use |
| WO2010120991A1 (en) | 2009-04-17 | 2010-10-21 | Wyeth Llc | 5, 6, 7, 8-tetrahydropyrido[4,3-d]pyrimidine compounds, their use as mtor, pi3, and hsmg-1 kinase inhibitors, and their syntheses |
| SG175259A1 (en) | 2009-04-20 | 2011-11-28 | Gilead Calistoga Llc | Methods of treatment for solid tumors |
| AR076435A1 (es) | 2009-04-30 | 2011-06-08 | Glaxo Group Ltd | Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos |
| EP2427195B1 (en) * | 2009-05-07 | 2019-05-01 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
| SG175708A1 (en) | 2009-05-27 | 2011-12-29 | Genentech Inc | Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
| EP2451811A1 (en) | 2009-05-27 | 2012-05-16 | F. Hoffmann-La Roche AG | Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
| EP2445898A2 (en) | 2009-06-25 | 2012-05-02 | Amgen, Inc | 4h-pyrido[1,2-a]pyrimidin-4-one derivatives as pi3k inhibitors |
| KR20140015121A (ko) | 2009-06-25 | 2014-02-06 | 암젠 인크 | 헤테로사이클릭 화합물 및 이의 용도 |
| EA201270013A1 (ru) | 2009-06-25 | 2012-06-29 | Амген Инк. | Гетероциклические соединения и их применение |
| MX2011013667A (es) | 2009-06-25 | 2012-03-06 | Amgen Inc | Compuestos heterociclicos y sus usos. |
| EP2845856A1 (en) | 2009-06-29 | 2015-03-11 | Incyte Corporation | Pyrimidinones as PI3K inhibitors |
| MX2012000103A (es) | 2009-07-02 | 2012-05-22 | Sanofi Sa | Nuevos derivados de 1,2,3,4-tetrahidro-pirimido (1,2-a) pirimidin-6-ona, su preparacion y su uso farmaceutica. |
| ES2627428T3 (es) | 2009-07-02 | 2017-07-28 | Sanofi | Nuevos derivados de 2,3-dihidro-1H-imidazo{1,2-a}pirimidin-5-ona, su preparación y su utilización farmacéutica |
| AU2010276160A1 (en) | 2009-07-21 | 2012-02-09 | Gilead Calistoga Llc | Treatment of liver disorders with PI3K inhibitors |
| AU2010286168B2 (en) | 2009-08-20 | 2014-05-15 | Karus Therapeutics Limited | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors |
| CN102741253A (zh) | 2009-09-29 | 2012-10-17 | 艾科睿控股公司 | PI3K(δ)选择性抑制剂 |
| GB0918249D0 (en) | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
| SG10201500895XA (en) | 2009-11-05 | 2015-04-29 | Rhizen Pharmaceuticals Sa | Chromen-4-one Derivatives As Kinase Modulators |
| WO2011055320A1 (en) | 2009-11-06 | 2011-05-12 | Piramal Life Sciences Limited | Imidazopyridine derivatives |
| EA201290305A1 (ru) | 2009-11-13 | 2012-12-28 | Мерк Сероно С.А. | Производные трициклического пиразоламина |
| JP2013512878A (ja) | 2009-12-03 | 2013-04-18 | グラクソ グループ リミテッド | 新規化合物 |
| JP2013512880A (ja) | 2009-12-03 | 2013-04-18 | グラクソ グループ リミテッド | Ｐｉ３−キナーゼ阻害剤としてのインダゾール誘導体 |
| WO2011067365A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Benzpyrazole derivatives as inhibitors of p13 kinases |
| US8759359B2 (en) | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
| WO2011075630A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors |
| MX2012006953A (es) | 2009-12-18 | 2012-10-09 | Amgen Inc | Compuestos heterociclicos y sus usos. |
| CN102762565A (zh) | 2010-02-22 | 2012-10-31 | 弗·哈夫曼-拉罗切有限公司 | 吡啶并[3,2-d]嘧啶PI3δ抑制剂化合物及使用方法 |
| UY33304A (es) | 2010-04-02 | 2011-10-31 | Amgen Inc | Compuestos heterocíclicos y sus usos |
| EP2558463A1 (en) | 2010-04-14 | 2013-02-20 | Incyte Corporation | Fused derivatives as i3 inhibitors |
| GB201007347D0 (en) | 2010-04-30 | 2010-06-16 | Karus Therapeutics Ltd | Compounds |
| AU2011255218B2 (en) | 2010-05-21 | 2015-03-12 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
| WO2011163195A1 (en) | 2010-06-21 | 2011-12-29 | Incyte Corporation | Fused pyrrole derivatives as pi3k inhibitors |
| UA112517C2 (uk) * | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
| CN103003279B (zh) | 2010-07-14 | 2015-09-23 | 弗·哈夫曼-拉罗切有限公司 | 对PI3K P110δ具有选择性的嘌呤化合物及其使用方法 |
| ES2612503T3 (es) | 2010-09-14 | 2017-05-17 | Exelixis, Inc. | Compuestos 9H-purina como inhibidores de PI3K-delta y métodos para su preparación |
| WO2012037204A1 (en) | 2010-09-14 | 2012-03-22 | Exelixis, Inc. | Inhibitors of pi3k-delta and methods of their use and manufacture |
| AU2012205669B2 (en) | 2011-01-10 | 2015-08-20 | Infinity Pharmaceuticals Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
| WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
| BR112013024122A2 (pt) | 2011-03-21 | 2019-09-24 | Hoffmann La Roche | compostos de benzoxazepina seletivos para p110 delta pi3k e métodos de uso |
| US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
| AU2012236722A1 (en) | 2011-03-28 | 2013-10-17 | Mei Pharma, Inc. | (alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases |
| US8530470B2 (en) | 2011-04-13 | 2013-09-10 | Astrazeneca Ab | Chromenone derivatives |
| EP2518070A1 (en) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Pyrrolotriazinone derivatives as PI3K inhibitors |
| EP2518071A1 (en) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Imidazopyridine derivatives as PI3K inhibitors |
| US20140249139A1 (en) | 2011-10-21 | 2014-09-04 | Novartis Ag | Quinazoline Derivatives |
| JP6117235B2 (ja) | 2011-12-15 | 2017-04-19 | ノバルティス アーゲー | Ｐｉ３ｋの活性または機能の阻害剤の使用 |
-
2012
- 2012-12-14 JP JP2014546719A patent/JP6117235B2/ja active Active
- 2012-12-14 DK DK12818825.7T patent/DK2790705T3/en active
- 2012-12-14 US US14/365,512 patent/US9949979B2/en active Active
- 2012-12-14 KR KR1020147019204A patent/KR102038462B1/ko active Active
- 2012-12-14 SI SI201231220T patent/SI2790705T1/en unknown
- 2012-12-14 AU AU2012354094A patent/AU2012354094C1/en active Active
- 2012-12-14 CN CN201280062139.8A patent/CN103998042B/zh active Active
- 2012-12-14 CA CA2857302A patent/CA2857302C/en active Active
- 2012-12-14 AP AP2014007679A patent/AP3849A/en active
- 2012-12-14 ES ES12818825.7T patent/ES2661510T3/es active Active
- 2012-12-14 EA EA201491182A patent/EA029473B1/ru not_active IP Right Cessation
- 2012-12-14 EP EP12818825.7A patent/EP2790705B1/en active Active
- 2012-12-14 PT PT128188257T patent/PT2790705T/pt unknown
- 2012-12-14 WO PCT/IB2012/057332 patent/WO2013088404A1/en not_active Ceased
- 2012-12-14 HU HUE12818825A patent/HUE036052T2/hu unknown
- 2012-12-14 PL PL12818825T patent/PL2790705T3/pl unknown
- 2012-12-14 MX MX2014007164A patent/MX351530B/es active IP Right Grant
- 2012-12-14 BR BR112014014327A patent/BR112014014327A2/pt not_active IP Right Cessation
-
2013
- 2013-07-04 NO NO13741876A patent/NO2896266T3/no unknown
-
2014
- 2014-05-23 TN TNP2014000230A patent/TN2014000230A1/en unknown
- 2014-06-13 GT GT201400114A patent/GT201400114A/es unknown
- 2014-06-13 PH PH12014501348A patent/PH12014501348A1/en unknown
- 2014-06-13 NI NI201400056A patent/NI201400056A/es unknown
- 2014-07-11 MA MA37198A patent/MA35857B1/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015500332A5 (enExample) | ||
| HRP20140778T1 (hr) | Derivati tetrahidro-pirido-pirimidina | |
| KR101677778B1 (ko) | 아미노피라진 유도체 및 의약 | |
| TWI875756B (zh) | Ｃｄｋ抑制劑 | |
| CN102791713B (zh) | 咪唑并[1,2-a]吡嗪衍生物及其预防或治疗神经病、精神病和代谢性障碍和疾病的用途 | |
| ES2572527T3 (es) | Inhibidores de PDE10 de pirimidina | |
| KR101985984B1 (ko) | 키나아제 저해제로서의 벤조니트릴 유도체 | |
| AU2015279377B2 (en) | Indolin-2-one or pyrrolo-pyridin-2-one derivatives | |
| CN102596961B (zh) | 咪唑并[1，2-b]哒嗪衍生物及其作为PDE10抑制剂的用途 | |
| JP2018515612A5 (enExample) | ||
| JP2014521711A5 (enExample) | ||
| JP2018515612A (ja) | 置換キノキサリン誘導体 | |
| JP2019535664A5 (enExample) | ||
| RU2012136643A (ru) | [5,6]- гетероциклическое соединение | |
| JP2015510938A5 (enExample) | ||
| HRP20201337T1 (hr) | Inhibitori lizin-specifične demetilaze-1 | |
| CA2798622A1 (en) | Indoles | |
| CN103313978A (zh) | 作为lrrk2调节剂的吡唑氨基嘧啶衍生物 | |
| HRP20180384T1 (hr) | Derivati 2,3-dihidro-benzo[1,4]oksazina i odgovarajući spojevi kao inhibitori kinaze fosfoinozitida-3 (pi3k) za liječenje primjerice reumatoidnog artritisa | |
| KR20140107421A (ko) | Pi3k의 활성 또는 기능의 억제제의 용도 | |
| JP2014528446A (ja) | １，３−置換アゼチジンｐｄｅ１０阻害剤 | |
| HRP20160649T1 (hr) | Novi derivati tienopirimidina, postupci za njihovo pripremanje i njihova terapeutska uporaba | |
| WO2012020786A1 (ja) | 医薬組成物 | |
| AU2013402175A1 (en) | Novel triazolopyrazine derivative and use thereof | |
| WO2012005299A1 (ja) | Ｒｏｓチロシンキナーゼ阻害剤 |